Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Baxalta Ventures

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 6
Average round size
info
The average size of a deal this fund participated in
$20M
Portfolio companies 3
Rounds per year 1.00
Lead investments 2
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.50
Exits 2
Key employees 1

Areas of investment

  • Biotechnology
  • Medical
  • Health Care
  • Pharmaceutical
  • Emergency Medicine
Summary

Baxalta Ventures is the famous VC, which was founded in 2015. The leading representative office of defined VC is situated in the Cambridge. The fund was located in North America if to be more exact in United States. Baxalta Ventures seemed to be an CVC arrangement as part of the organization.

The overall number of key employees were 1.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Moreover, a startup needs to be at the age of 2-3 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Syntimmune, Gadeta, True North Therapeutics The fund has exact preference in some founders of portfolio startups. We can highlight the next thriving fund investment areas, such as Clinical Trials, Health Care.

The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the Baxalta Ventures, startups are often financed by Partners Innovation Fund, Apple Tree Partners, SR One. The meaningful sponsors for the fund in investment in the same round are Partners Innovation Fund, Apple Tree Partners, Utrecht Holdings. In the next rounds fund is usually obtained by Partners Innovation Fund, Apple Tree Partners, SR One.

Opposing the other organizations, this Baxalta Ventures works on 4 percentage points more the average amount of lead investments. The top activity for fund was in 2016. The higher amount of exits for fund were in 2018. The fund is constantly included in less than 2 deals per year. Considering the real fund results, this VC is 13 percentage points more often commits exit comparing to other organizations. Deals in the range of 10 - 50 millions dollars are the general things for fund.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Baxalta Ventures:
Typical Co-investors
Baxalta Ventures is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Baxalta Ventures:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Accenture County Dublin, Dublin, Ireland
another.vc Berlin, Berlin, Germany
Arcadia Funds Burlington, Massachusetts, United States
Ayce Capital Partners Barcelona, Catalonia, Spain
BioVeda China Fund China, Shanghai
DocuSign California, San Francisco, United States
Goff Capital Fort Worth, Texas, United States
GreatWall Fund China, Guangdong, Shenzhen
HgCapital Trust plc England, London, United Kingdom
Huis Ten Bosch Chiba Prefecture, Futtsu, Japan
IND Fund -
London School of Economics and Political Science (LSE) England, London, United Kingdom
Maker Studios California, Culver City, United States
Matrix Herzliya, Israel, Tel Aviv
Ogaki Kyoritsu Bank Gifu Prefecture, Japan, Ogaki
Queen City Angels First Funds Cincinnati, Ohio, United States
Standard Industries New York, New York, United States
startGBC Canada, Ontario, Toronto
Valor Ena, Gifu Prefecture, Japan
Yaba Ziguan China, Qingpu, Shanghai

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Syntimmune

Biotechnology
Emergency Medicine
Health Care
Medical
Pharmaceutical
$50M21 Jun 2017 Boston, Massachusetts, United States

Syntimmune

Biotechnology
Emergency Medicine
Health Care
Medical
Pharmaceutical
$8M17 Nov 2016 Boston, Massachusetts, United States

Gadeta

Biotechnology
Medical
Therapeutics
$8M29 Mar 2016 Utrecht

Syntimmune

Biotechnology
Emergency Medicine
Health Care
Medical
Pharmaceutical
$10M22 Mar 2016 Boston, Massachusetts, United States

True North Therapeutics

Biotechnology
Clinical Trials
Health Care
$40M03 Dec 2015 South San Francisco, California, United States

Syntimmune

Biotechnology
Emergency Medicine
Health Care
Medical
Pharmaceutical
$8M24 Oct 2014 Boston, Massachusetts, United States

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Baxalta Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 6
Average round size 20M
Rounds per year 1.00
Peak activity year 2016
Lead investments 2
Follow on index 0.50
Exits 2
Group Appearance index 1.00

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Syntimmune

Biotechnology
Emergency Medicine
Health Care
Medical
Pharmaceutical
$50M21 Jun 2017 Boston, Massachusetts, United States

Syntimmune

Biotechnology
Emergency Medicine
Health Care
Medical
Pharmaceutical
$8M17 Nov 2016 Boston, Massachusetts, United States

Gadeta

Biotechnology
Medical
Therapeutics
$8M29 Mar 2016 Utrecht

Syntimmune

Biotechnology
Emergency Medicine
Health Care
Medical
Pharmaceutical
$10M22 Mar 2016 Boston, Massachusetts, United States

True North Therapeutics

Biotechnology
Clinical Trials
Health Care
$40M03 Dec 2015 South San Francisco, California, United States

Syntimmune

Biotechnology
Emergency Medicine
Health Care
Medical
Pharmaceutical
$8M24 Oct 2014 Boston, Massachusetts, United States
Crunchbase icon

Content report

The following text will be sent to our editors: